Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Average Ratings 0 Ratings

Total
ease
features
design
support

No User Reviews. Be the first to provide a review:

Write a Review

Description

CoVigilAI is a cutting-edge solution for monitoring medical literature that leverages artificial intelligence and sophisticated data analysis to identify and manage adverse drug reactions proactively, thereby safeguarding patient well-being and adhering to regulatory standards in real time. This platform simplifies the tracking of scientific and medical literature by sourcing information from major global databases like PubMed and Embase, offering customizable search parameters that enhance the pharmacovigilance literature review process. Additionally, it systematically reviews scientific articles and publications from various local journals, ensuring comprehensive global and localized literature oversight. Utilizing advanced algorithms, the system classifies Individual Case Safety Reports (ICSRs) into three categories: valid, potential, and invalid cases, while its automated key entity recognition capability adeptly identifies essential elements such as patients, medications, adverse reactions, and relevant medical events. This holistic approach not only streamlines the monitoring process but also significantly enhances the accuracy and efficiency of drug safety assessments.

Description

Pharmaceutical companies require extensive genomic data to effectively implement precision medicine initiatives; however, they frequently rely on merely 10% of the available information for their decisions. Genomenon provides access to the complete dataset. Their Prodigy™ Patient Landscapes offer a streamlined and economical solution for natural history research, aiding the creation of therapies for rare diseases by deepening understanding of both retrospective and prospective health data. Utilizing an advanced AI-driven methodology, Genomenon conducts a thorough evaluation of each patient documented in the medical literature in a significantly reduced timeframe. Ensure you capture all relevant insights by exploring every genomic biomarker featured in published studies. Each scientific claim is substantiated by concrete evidence drawn from the medical literature, allowing researchers to uncover all genetic drivers and identify variants recognized as pathogenic in accordance with ACMG clinical standards, thereby enhancing the development process of targeted therapies. By leveraging this comprehensive approach, pharma companies can enhance their research effectiveness and ultimately improve patient outcomes.

API Access

Has API No 

API Access

Has API Yes 

Screenshots View All

Screenshots View All

Integrations

Embase Yes 
Google Cloud Platform No 
PubMed Yes 

Integrations

Embase No 
Google Cloud Platform Yes 
PubMed No 

Pricing Details

No price information available.
Free Trial No 
Free Version No 

Pricing Details

No price information available.
Free Trial No 
Free Version No 

Deployment

Web-Based Yes 
On-Premises No 
iPhone App No 
iPad App No 
Android App No 
Windows No 
Mac No 
Linux No 
Chromebook No 

Deployment

Web-Based Yes 
On-Premises No 
iPhone App No 
iPad App No 
Android App No 
Windows No 
Mac No 
Linux No 
Chromebook No 

Customer Support

Business Hours Yes 
Live Rep (24/7) No 
Online Support Yes 

Customer Support

Business Hours Yes 
Live Rep (24/7) No 
Online Support Yes 

Types of Training

Training Docs Yes 
Webinars No 
Live Training (Online) Yes 
In Person Yes 

Types of Training

Training Docs Yes 
Webinars Yes 
Live Training (Online) Yes 
In Person Yes 

Vendor Details

Company Name

CoVigilAI

Country

India

Website

covigilai.in/

Vendor Details

Company Name

Genomenon

Country

United States

Website

www.genomenon.com/pharma/

Product Features

Alternatives

Dialog Reviews

Dialog

Clarivate

Alternatives

VSClinical Reviews

VSClinical

Golden Helix
Compier Literature Screening Reviews

Compier Literature Screening

Techsol Life Sciences